Ignite Creation Date:
2024-05-05 @ 12:00 PM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00201981
Status:
COMPLETED
Last Update Posted:
2008-01-07
First Post:
2005-09-12
Brief Title:
Study of Rebamipide Eye Drops to Treat Dry Eye
Sponsor:
Otsuka Pharmaceutical Development Commercialization Inc
Organization:
Otsuka Pharmaceutical Development Commercialization Inc
Study Overview
Official Title:
Rebamipide Ophthalmic Suspension in the Treatment of Dry Eye A Multicenter Phase 3 Randomized Double-Masked Placebo-Controlled Parallel-Group 52 Week Study
Status:
COMPLETED
Status Verified Date:
2008-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the potential safety and effectiveness of rebamipide eye drops an investigational eye drop being developed for the treatment of keratoconjunctivitis sicca dry eye
Detailed Description:
There is a need for effective therapy for dry eye that treats the underlying cause of the syndrome The goal of this study is to assess the impact of rebamipide on dry eye symptom
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None